An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (INSIGHT)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Janssen-Cilag International NV
ClinicalTrials.gov Identifier:
NCT01513941
First received: January 16, 2012
Last updated: March 17, 2014
Last verified: March 2014

January 16, 2012
March 17, 2014
April 2012
June 2014   (final data collection date for primary outcome measure)
Proportion of patients achieving undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels [ Time Frame: Up to 48 weeks ] [ Designated as safety issue: No ]
Proportion of patients achieving sustained virologic response (SVR) undetectable plasma HCV RNA levels 12 weeks after the last planned dose of study medication.
Proportion of patients achieving undetectable plasma HCV ribonucleic acid (RNA) levels [ Time Frame: 12 weeks after the last planned dose of study drug ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01513941 on ClinicalTrials.gov Archive Site
  • Change from baseline in log HCV RNA values [ Time Frame: Baseline and week 48 ] [ Designated as safety issue: No ]
    Change from baseline in log HCV RNA values at each time point during treatment.
  • Proportiond of patients achieving undetectable HCV RNA levels [ Time Frame: Up to 48 weeks ] [ Designated as safety issue: No ]
    Proportion of patients achieving SVR24 planned, defined as having undetectable plasma HCV RNA levels 24 weeks after the last planned dose of study medication.
  • Proportion of patients achieving undetectable HCV RNA levels at Week 4 [ Time Frame: Up to 48 weeks ] [ Designated as safety issue: No ]
    The proportion of patients who achieve rapid virologic response (RVR) and undetectable HCV RNA levels at Week 4 of treatment.
  • Proportion of patients achieving undetectable HCV RNA levels at Week 12 [ Time Frame: Up to 48 weeks ] [ Designated as safety issue: No ]
    Proportion of patients achieving undetectable HCV RNA levels at Week 12 of treatment.
  • Proportion of patients achieving undetectable HCV RNA levels at Week 4 and Week 12 (eRVR) [ Time Frame: Up to 48 weeks ] [ Designated as safety issue: No ]
    Proportion of patients achieving undetectable HCV RNA levels at Week 4 and Week 12 of treatment (eRVR).
  • Proportion of patients achieving undetectable HCV RNA at the actual end of treatment [ Time Frame: Up to 48 weeks ] [ Designated as safety issue: No ]
    Proportion of patients having undetectable HCV RNA levels at the actual end of treatment (ie, Week 24, Week 48, or early discontinuation).
  • Proportion of patients achieving less than 25 IU/mL [ Time Frame: Up to 48 weeks ] [ Designated as safety issue: No ]
    Proportion of patients having less than 25 IU/mL at the planned end of treatment (ie, Week 24 or Week 48).
  • Proportion of patients with on-treatment virologic failure [ Time Frame: Up to 48 weeks ] [ Designated as safety issue: No ]
    Proportion of patients with on-treatment virologic failure (an increase greater than 1 log in HCV RNA level from the lowest level reached, or a value of HCV RNA greater than 100 IU/mL in patients whose HCV RNA has previously become less than 25 IU/mL during treatment).
  • Proportion of patients with relapse achieving detectable HCV RNA levels after previously undetectable HCV RNA levels [ Time Frame: Up to 48 weeks ] [ Designated as safety issue: No ]
    Proportion of patients who relapse (having confirmed detectable HCV RNA during the follow-up period after previous undetectable HCV RNA levels (less than 25 IU/mL, undetectable) at planned end of treatment.
  • Proportion of patients with relapse achieving detectable HCV RNA levels after previous HCV RNA levels [ Time Frame: Up to 48 weeks ] [ Designated as safety issue: No ]
    Proportion of patients who relapse, defined as having confirmed detectable HCV RNA during the follow-up period after previous HCV RNA less than 25 IU/mL at planned end of treatment.
Not Provided
Not Provided
Not Provided
 
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects With Genotype 1 Chronic Hepatitis C and Human Immunodeficiency Virus Type 1 (HCV-1/HIV-1) Coinfection

The purpose of this study is to evaluate the effectiveness and safety of telaprevir, given with pegylated-interferon-alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in the treatment of hepatitis C in patients infected with both chronic hepatitis C virus (HCV-1) and human immunodeficiency virus (HIV-1).

This is an open-label (both participant and investigator know the name of the medication given at a certain moment), single-arm, multicenter study in HCV treatment-naive and treatment-experienced patients infected with both chronic HCV-1 and HIV-1 to determine the efficacy and safety of telaprevir given with Peg-IFN-alfa-2a and RBV. The study will consist of 3 phases: a screening phase, an open-label treatment phase up to 48 weeks, and a follow-up period of 24 weeks. All patients will receive 12 weeks of treatment with telaprevir given with Peg-IFN-alfa-2a and RBV. At week 12 telaprevir dosing will end and patients will continue on Peg-IFN-alfa-2a and RBV. The total treatment duration in this study will be 24 or 48 weeks depending on the patient's prior HCV treatment status, liver disease status, and individual on-treatment virologic response in this study (equal response guided therapy). The maximum total duration of participation in the study for an individual participant will be approximately 76 weeks (screening included). Approximately 150 patients infected with both chronic HCV-1 and HIV-1 are planned to be enrolled.

Interventional
Phase 3
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Chronic Hepatitis C
  • Drug: Telaprevir
    Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
  • Drug: Ribavirin
    Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
  • Drug: Pegylated-Interferon-alfa-2a
    Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
Experimental: Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV)
All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.
Interventions:
  • Drug: Telaprevir
  • Drug: Ribavirin
  • Drug: Pegylated-Interferon-alfa-2a
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
163
June 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Chronic (detectable HCV Ribonucleic acid (RNA) more than 6 months prior screening or histological diagnosis based on liver biopsy or fibroscan) HCV infection genotype 1 with HCV RNA level greater than 1,000 IU/mL
  • Confirmed diagnosis of HIV-1 infection greater than 6 months before the screening visit
  • CD4 count greater than 300 cells/mm3 at screening and no value less than 200 cells/mm3 within 6 months of screening visit
  • HIV-1 RNA undetectable by an ultrasensitive assay at least once within 90 days of the screening visit
  • No HIV RNA values greater than 200 copies/mL within 6 months of the screening visit
  • Currently taking one of the permitted anti-HIV regimens for greater than or equal to12 weeks

Exclusion Criteria:

  • Anticipated need to switch anti-HIV regimen from screening through the Telaprevir treatment period
  • Infection or co-infection with HCV other than genotype 1
  • Contraindication to the administration of Peg-IFN-alfa or RBV
  • Hepatitis B virus (HBV) co-infection
  • Acute or active condition of HIV-associated opportunistic infection within 6 months of screening
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Brazil,   France,   Poland,   Russian Federation,   Spain,   Sweden,   United Kingdom
 
NCT01513941
CR100778, VX-950HPC3008, 2011-004928-35
No
Janssen-Cilag International NV
Janssen-Cilag International NV
Not Provided
Study Director: Janssen-Cilag International NV, Belgium Clinical Trial Janssen-Cilag International NV
Janssen-Cilag International NV
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP